Compare AQN & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AQN | PTCT |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | Canada | United States |
| Employees | N/A | 991 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.0B |
| IPO Year | 2002 | 2006 |
| Metric | AQN | PTCT |
|---|---|---|
| Price | $5.60 | $60.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 15 |
| Target Price | $6.55 | ★ $100.40 |
| AVG Volume (30 Days) | ★ 3.2M | 1.0M |
| Earning Date | 11-06-2026 | 10-29-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | N/A | ★ 0.34 |
| Revenue | N/A | ★ $264,734,000.00 |
| Revenue This Year | $7.71 | N/A |
| Revenue Next Year | $4.41 | $8.21 |
| P/E Ratio | ★ N/A | $177.71 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $4.91 | $58.80 |
| 52 Week High | $7.11 | $90.87 |
| Indicator | AQN | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 67.17 | 43.92 |
| Support Level | $5.49 | $58.80 |
| Resistance Level | $6.06 | $63.74 |
| Average True Range (ATR) | 0.11 | 2.33 |
| MACD | 0.04 | 0.22 |
| Stochastic Oscillator | 97.17 | 31.73 |
Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units: the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution, and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.